SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
5.10
-0.12 (-2.30%)
Aug 21, 2026, 4:00 PM EDT - Market closed
SCYNEXIS Revenue
SCYNEXIS had revenue of $235.00K in the quarter ending June 30, 2026, a decrease of -82.77%. This brings the company's revenue in the last twelve months to $17.77M, up 445.46% year-over-year. In the year 2025, SCYNEXIS had annual revenue of $41.20M with 449.95% growth.
Revenue (ttm)
$17.77M
Revenue Growth
+445.46%
P/S Ratio
2.64
Revenue / Employee
$1,067,556
Employees
18
Market Cap
50.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.20M | 33.71M | 449.95% |
| Dec 31, 2024 | 7.49M | -272.79M | -97.33% |
| Dec 31, 2023 | 280.28M | 270.10M | 2,652.72% |
| Dec 31, 2022 | 10.18M | -16.14M | -61.32% |
| Dec 31, 2021 | 26.33M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 121.00K | -136.00K | -52.92% |
| Dec 31, 2018 | 257.00K | - | - |
| Dec 31, 2017 | 257.00K | - | - |
| Dec 31, 2016 | 257.00K | - | - |
| Dec 31, 2015 | 257.00K | -999.00K | -79.54% |
| Dec 31, 2014 | 1.26M | -15.60M | -92.55% |
| Dec 31, 2013 | 16.86M | 20.00K | 0.12% |
| Dec 31, 2012 | 16.84M | -9.62M | -36.35% |
| Dec 31, 2011 | 26.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| InterCure | 84.76M |
| Rockwell Medical | 69.39M |
| Aytu BioPharma | 56.60M |
| BGM Group | 37.92M |
| Zhengye Biotechnology Holding | 16.64M |
| China Pharma Holdings | 3.91M |
| BioXcel Therapeutics | 742.00K |
| Optimi Health | 123.70K |
SCYX News
- 6 days ago - Scynexis price target raised to $33 from $24 at Guggenheim - TheFly
- 12 days ago - Scynexis reports Q2 EPS 63c, consensus (51c) - TheFly
- 13 days ago - SCYNEXIS Quarterly report: Q2 2026 - Filings
- 13 days ago - SCYNEXIS Earnings release: Q2 2026 - Filings
- 7 weeks ago - Scynexis initiates SCY-770 study - TheFly
- 7 weeks ago - SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - GlobeNewsWire
- 2 months ago - SCYNEXIS Transcript: AGM 2026 - Transcripts
- 3 months ago - Scynexis trading halted, news pending - TheFly